Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07122076 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 65 words
    • Secondary endpoints: details revised at 3 of 3 entries
  2. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Aug 19, 2028 to Aug 21, 2028
    • Start date changed from estimate of Aug 20, 2025 to Aug 22, 2025
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a prospective single-arm open-label clinical trial, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in patients with moderate to severe refractory autoimmune diseases. A total of 10 subjects will be enrolled in this study.
Trial Details
NCT Number NCT07122076
Lead Sponsor Grit Biotechnology
Conditions
(from sponsor)		 Autoimmune Diseases
Related terms Autoimmune Diseases
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov